GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2696781&ei=kXKaUvDOH7Hr0QGFIA&usg=AFQjCNF7Owskiphx88BCFLkr5H1hTuS-vw
Gilead Sciences Inc And Teva Pharmaceuticals Reach Settlement Agreement In Viread Patent Litigation
Tuesday, 19 Feb 2013 11:05pm EST
Gilead Sciences Inc announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017. The trial in this litigation, which was scheduled to begin on Wednesday, February 20 in the District Court for the Southern District of New York, has been adjourned pending completion of activities necessary to finalize the settlement.Â 
